Portopulmonary hypertension: Difference between revisions
CSV import |
CSV import |
||
| Line 1: | Line 1: | ||
{{Infobox medical condition | |||
| name = Portopulmonary hypertension | |||
| synonyms = | |||
| image = | |||
| caption = | |||
| field = [[Cardiology]], [[Pulmonology]] | |||
| symptoms = [[Dyspnea]], [[fatigue]], [[chest pain]], [[syncope]] | |||
| complications = [[Right heart failure]], [[gastrointestinal bleeding]] | |||
| onset = | |||
| duration = | |||
| types = | |||
| causes = [[Portal hypertension]] | |||
| risks = [[Liver cirrhosis]], [[hepatitis]], [[alcohol use disorder]] | |||
| diagnosis = [[Echocardiography]], [[right heart catheterization]] | |||
| differential = [[Pulmonary arterial hypertension]], [[chronic thromboembolic pulmonary hypertension]] | |||
| prevention = | |||
| treatment = [[Vasodilators]], [[liver transplantation]] | |||
| medication = [[Prostacyclin]], [[endothelin receptor antagonists]], [[phosphodiesterase-5 inhibitors]] | |||
| prognosis = Variable, depends on severity and treatment | |||
| frequency = Rare | |||
}} | |||
'''Portopulmonary hypertension''' (PoPH) is a form of [[pulmonary hypertension]] (PH) that occurs in individuals with [[portal hypertension]], often due to [[cirrhosis]] of the [[liver]]. It is defined by the presence of pulmonary arterial hypertension (PAH) in the setting of portal hypertension. | '''Portopulmonary hypertension''' (PoPH) is a form of [[pulmonary hypertension]] (PH) that occurs in individuals with [[portal hypertension]], often due to [[cirrhosis]] of the [[liver]]. It is defined by the presence of pulmonary arterial hypertension (PAH) in the setting of portal hypertension. | ||
==Epidemiology== | ==Epidemiology== | ||
PoPH is estimated to occur in approximately 5-10% of individuals with portal hypertension. The exact prevalence is unknown due to the lack of large-scale epidemiological studies. However, it is known that the condition is more common in individuals with advanced liver disease. | PoPH is estimated to occur in approximately 5-10% of individuals with portal hypertension. The exact prevalence is unknown due to the lack of large-scale epidemiological studies. However, it is known that the condition is more common in individuals with advanced liver disease. | ||
==Pathophysiology== | ==Pathophysiology== | ||
The pathophysiology of PoPH is complex and not fully understood. It is thought to involve an imbalance between vasoconstrictive and vasodilative mediators in the pulmonary circulation, leading to increased pulmonary vascular resistance and pulmonary arterial pressure. This is often accompanied by vascular remodeling and thrombosis in situ. | The pathophysiology of PoPH is complex and not fully understood. It is thought to involve an imbalance between vasoconstrictive and vasodilative mediators in the pulmonary circulation, leading to increased pulmonary vascular resistance and pulmonary arterial pressure. This is often accompanied by vascular remodeling and thrombosis in situ. | ||
==Clinical Presentation== | ==Clinical Presentation== | ||
Patients with PoPH may present with symptoms of both portal hypertension and pulmonary hypertension. These can include [[shortness of breath]], [[fatigue]], [[syncope]], and signs of right heart failure such as [[edema]] and [[ascites]]. In many cases, the symptoms of pulmonary hypertension may be masked by the underlying liver disease, making diagnosis challenging. | Patients with PoPH may present with symptoms of both portal hypertension and pulmonary hypertension. These can include [[shortness of breath]], [[fatigue]], [[syncope]], and signs of right heart failure such as [[edema]] and [[ascites]]. In many cases, the symptoms of pulmonary hypertension may be masked by the underlying liver disease, making diagnosis challenging. | ||
==Diagnosis== | ==Diagnosis== | ||
The diagnosis of PoPH is made based on a combination of clinical findings, imaging studies, and hemodynamic measurements. [[Echocardiography]] is often the first step in the diagnostic process, followed by right heart catheterization to confirm the diagnosis and assess the severity of the disease. | The diagnosis of PoPH is made based on a combination of clinical findings, imaging studies, and hemodynamic measurements. [[Echocardiography]] is often the first step in the diagnostic process, followed by right heart catheterization to confirm the diagnosis and assess the severity of the disease. | ||
==Treatment== | ==Treatment== | ||
The treatment of PoPH involves managing the underlying liver disease, treating the pulmonary hypertension, and in some cases, liver transplantation. Medications used to treat pulmonary hypertension, such as [[endothelin receptor antagonists]], [[phosphodiesterase-5 inhibitors]], and [[prostacyclin analogues]], may also be used in the treatment of PoPH. | The treatment of PoPH involves managing the underlying liver disease, treating the pulmonary hypertension, and in some cases, liver transplantation. Medications used to treat pulmonary hypertension, such as [[endothelin receptor antagonists]], [[phosphodiesterase-5 inhibitors]], and [[prostacyclin analogues]], may also be used in the treatment of PoPH. | ||
==Prognosis== | ==Prognosis== | ||
The prognosis of PoPH is generally poor, with a median survival of less than 3 years in untreated patients. However, with appropriate treatment, survival can be significantly improved. | The prognosis of PoPH is generally poor, with a median survival of less than 3 years in untreated patients. However, with appropriate treatment, survival can be significantly improved. | ||
[[Category:Medical conditions]] | [[Category:Medical conditions]] | ||
[[Category:Pulmonary hypertension]] | [[Category:Pulmonary hypertension]] | ||
| Line 24: | Line 39: | ||
{{stub}} | {{stub}} | ||
{{No image}} | {{No image}} | ||
Latest revision as of 03:52, 4 April 2025
| Portopulmonary hypertension | |
|---|---|
| Synonyms | |
| Pronounce | N/A |
| Specialty | N/A |
| Symptoms | Dyspnea, fatigue, chest pain, syncope |
| Complications | Right heart failure, gastrointestinal bleeding |
| Onset | |
| Duration | |
| Types | |
| Causes | Portal hypertension |
| Risks | Liver cirrhosis, hepatitis, alcohol use disorder |
| Diagnosis | Echocardiography, right heart catheterization |
| Differential diagnosis | Pulmonary arterial hypertension, chronic thromboembolic pulmonary hypertension |
| Prevention | |
| Treatment | Vasodilators, liver transplantation |
| Medication | Prostacyclin, endothelin receptor antagonists, phosphodiesterase-5 inhibitors |
| Prognosis | Variable, depends on severity and treatment |
| Frequency | Rare |
| Deaths | N/A |
Portopulmonary hypertension (PoPH) is a form of pulmonary hypertension (PH) that occurs in individuals with portal hypertension, often due to cirrhosis of the liver. It is defined by the presence of pulmonary arterial hypertension (PAH) in the setting of portal hypertension.
Epidemiology[edit]
PoPH is estimated to occur in approximately 5-10% of individuals with portal hypertension. The exact prevalence is unknown due to the lack of large-scale epidemiological studies. However, it is known that the condition is more common in individuals with advanced liver disease.
Pathophysiology[edit]
The pathophysiology of PoPH is complex and not fully understood. It is thought to involve an imbalance between vasoconstrictive and vasodilative mediators in the pulmonary circulation, leading to increased pulmonary vascular resistance and pulmonary arterial pressure. This is often accompanied by vascular remodeling and thrombosis in situ.
Clinical Presentation[edit]
Patients with PoPH may present with symptoms of both portal hypertension and pulmonary hypertension. These can include shortness of breath, fatigue, syncope, and signs of right heart failure such as edema and ascites. In many cases, the symptoms of pulmonary hypertension may be masked by the underlying liver disease, making diagnosis challenging.
Diagnosis[edit]
The diagnosis of PoPH is made based on a combination of clinical findings, imaging studies, and hemodynamic measurements. Echocardiography is often the first step in the diagnostic process, followed by right heart catheterization to confirm the diagnosis and assess the severity of the disease.
Treatment[edit]
The treatment of PoPH involves managing the underlying liver disease, treating the pulmonary hypertension, and in some cases, liver transplantation. Medications used to treat pulmonary hypertension, such as endothelin receptor antagonists, phosphodiesterase-5 inhibitors, and prostacyclin analogues, may also be used in the treatment of PoPH.
Prognosis[edit]
The prognosis of PoPH is generally poor, with a median survival of less than 3 years in untreated patients. However, with appropriate treatment, survival can be significantly improved.
